Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30128750 | 1.00 | ATM (0.50) | ATML3MBTL1CYP3A4CYP2D6CHRM3 | |
| SCHEMBL6425438 | 0.86 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL1004280 | 0.85 | CHRM3 (0.54) | CHRM3RBP4ALDH1A1 | |
| SCHEMBL15935217 | 0.77 | HTR2A (0.46) | ATML3MBTL1CYP2D6 | |
| SCHEMBL13416029 | 0.76 | HTR2A (0.58) | RBP4 | |
| SCHEMBL17871674 | 0.76 | ALDH1A1 (0.52) | ATML3MBTL1CYP3A4CYP2D6CHRM3 | |
| Benzylic Acid SCHEMBL28790412 | 0.75 | CHRM3 (0.54) | ATML3MBTL1CYP3A4CYP2D6CHRM3 | |
| SCHEMBL5160638 | 0.75 | IKBKB (0.41) | — | |
| SCHEMBL30830968 | 0.75 | MYC (0.47) | ATML3MBTL1CYP2D6 | |
| Bromomethane SCHEMBL19839345 | 0.74 | ALDH1A1 (0.50) | ATML3MBTL1CYP3A4CYP2D6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | claimed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | claimed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | claimed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | claimed |
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-10100012-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2018-10-16 | — | — | US | disclosed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100012-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | ATM 2779/4885L3MBTL1 4594/4885CYP3A4 527/4885 |
| US-10207993-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | ATM 2779/4885L3MBTL1 4594/4885CYP3A4 527/4885 |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | ATM 2570/4885L3MBTL1 4494/4885CYP3A4 1284/4885 |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | ATM 2570/4885L3MBTL1 4494/4885CYP3A4 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.